MCID: SWN001
MIFTS: 44

Swine Influenza malady

Categories: Respiratory diseases, Infectious diseases

Aliases & Classifications for Swine Influenza

Summaries for Swine Influenza

CDC : 3 Swine influenza is a respiratory disease of pigs caused by type A influenza viruses that regularly cause outbreaks of influenza in pigs. Influenza viruses that commonly circulate in swine are called “swine influenza viruses” or “swine flu viruses.” Like human influenza viruses, there are different subtypes and strains of swine influenza viruses. The main swine influenza viruses circulating in U.S. pigs in recent years have been, swine triple reassortant (tr) H1N1 influenza virus, trH3N2 virus, and trH1N2 virus.

MalaCards based summary : Swine Influenza, also known as influenza due to influenza a virus subtype h1n1, is related to influenza and pneumonia, and has symptoms including fever, lethargy and lack of appetite. An important gene associated with Swine Influenza is GP2 (Glycoprotein 2). The drugs Vitamin A and Vitamin C have been mentioned in the context of this disorder. Affiliated tissues include lung, testes and t cells, and related phenotype is integument.

Disease Ontology : 12 An influenza that results_in infection located in respiratory tract of pigs and humans, has material basis in Influenza C virus, or has material basis in Influenza A virus subtypes (H1N1, H1N2, H3N1, H3N2, and H2N3), which are transmitted_by direct contact with infected pigs. The infection in humans has symptom fever, has symptom lethargy, has symptom lack of appetite, has symptom coughing, has symptom runny nose, has symptom sore throat, has symptom nausea, has symptom vomiting, and has symptom diarrhea.

Wikipedia : 71 Swine influenza, also called pig influenza, swine flu, hog flu and pig flu, is an infection caused by... more...

Related Diseases for Swine Influenza

Diseases related to Swine Influenza via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 31)
id Related Disease Score Top Affiliating Genes
1 influenza 11.0
2 pneumonia 10.3
3 colon adenocarcinoma 10.0 TGM3 TNF
4 glandular tularemia 10.0 GP2 HAS1
5 avian influenza 10.0
6 central nervous system angiosarcoma 9.9 HAS1 NEU1 TNF
7 lymphopenia 9.8
8 systemic lupus erythematosus 9.8
9 appendicitis 9.8
10 respiratory failure 9.8
11 lupus erythematosus 9.8
12 narcolepsy 9.8
13 cerebritis 9.8
14 mouth disease 9.6
15 rheumatoid arthritis 9.6
16 acute disseminated encephalomyelitis 9.6
17 myocardial infarction 9.6
18 myocarditis 9.6
19 arthritis 9.6
20 thrombocytopenia 9.6
21 chronic fatigue syndrome 9.6
22 infective endocarditis 9.6
23 neuropathy 9.6
24 endocarditis 9.6
25 smallpox 9.6
26 pleuropneumonia 9.6
27 vaccinia 9.6
28 parainfluenza virus type 3 9.6
29 virus associated hemophagocytic syndrome 9.6
30 plague 9.6
31 selective igm deficiency disease 8.6 AGO1 FGD1 GP2 HAS1 NEU1 SLC8B1

Graphical network of the top 20 diseases related to Swine Influenza:



Diseases related to Swine Influenza

Symptoms & Phenotypes for Swine Influenza

Symptoms:

12
  • fever
  • lethargy
  • lack of appetite
  • coughing
  • runny nose
  • sore throat
  • nausea
  • vomiting
  • diarrhea

UMLS symptoms related to Swine Influenza:


coughing, fever, pruritus, snoring

MGI Mouse Phenotypes related to Swine Influenza:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 integument MP:0010771 9.02 AGO1 NEU1 SLC8B1 TGM3 TNF

Drugs & Therapeutics for Swine Influenza

Drugs for Swine Influenza (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 55)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 11103-57-4, 68-26-8 445354
2
Vitamin C Approved, Nutraceutical Phase 4 50-81-7 5785 54670067
3 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
4 Antioxidants Phase 4
5 Antipyretics Phase 4
6 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
7 Micronutrients Phase 4
8 Protective Agents Phase 4,Phase 1
9 Retinol palmitate Phase 4
10 Trace Elements Phase 4
11 Vitamins Phase 4
12 Vaccines Phase 4,Phase 2,Phase 3,Phase 1
13 Antibodies Phase 4,Phase 2,Phase 1
14 Immunoglobulins Phase 4,Phase 2,Phase 1
15
Lactitol Phase 4,Phase 3,Phase 2 585-86-4 3871
16 MF59 oil emulsion Phase 4,Phase 2,Phase 3,Phase 1
17 Immunosuppressive Agents Phase 4
18 Hemagglutinins Phase 4,Phase 2,Phase 1
19 retinol Nutraceutical Phase 4
20
Oseltamivir Approved Phase 3,Phase 2 204255-11-8, 196618-13-0 65028
21
Zanamivir Approved, Investigational Phase 3,Phase 2 139110-80-8 60855
22
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754 657311
23
Butyric Acid Experimental Phase 3 107-92-6 264
24 Adjuvants, Immunologic Phase 2, Phase 3
25 Anti-Inflammatory Agents Phase 3,Phase 2
26 Cortisol succinate Phase 3
27 Hydrocortisone 17-butyrate 21-propionate Phase 3
28 Hydrocortisone acetate Phase 3
29 Hydrocortisone-17-butyrate Phase 3
30
Interferon alfacon-1 Approved Phase 1, Phase 2 118390-30-0 9554198
31
Thymalfasin Approved, Investigational Phase 2 62304-98-7
32 interferons Phase 1, Phase 2
33 Pharmaceutical Solutions Phase 2
34 Agglutinins Phase 1, Phase 2
35 Anti-Bacterial Agents Phase 2
36 Antibiotics, Antitubercular Phase 2
37 Antibodies, Monoclonal Phase 2
38 Anticholesteremic Agents Phase 2
39 Antimetabolites Phase 2
40 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 2
41 Hypolipidemic Agents Phase 2
42 Lipid Regulating Agents Phase 2
43 Calcium, Dietary Phase 2
44 Rosuvastatin Calcium Phase 2 147098-20-2
45 Aluminum sulfate Phase 1
46 Cariostatic Agents Phase 1
47 potassium phosphate Phase 1
48 arginine Nutraceutical Phase 1
49 Glutamic Acid Nutraceutical Phase 1
50 Interleukin-2

Interventional clinical trials:

(show top 50) (show all 168)
id Name Status NCT ID Phase
1 The Impact of Vitamin on the Clinical Course in Cases Infected by Novel H1N1 Influenza Virus A Unknown status NCT01127282 Phase 4
2 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
3 Safety and Immune Response to Adjuvanted A(H1N1)v Influenza Vaccine in HIV-1 Infected and Immunosuppressed Adult Patients Unknown status NCT01017172 Phase 4
4 Open-label, Uncontrolled Postmarketing Study of Cell-derived A/H1N1 Influenza HA Vaccine in Japanese Elderly Subjects Completed NCT01069367 Phase 4
5 H1N1 Influenza Vaccine Immunogenicity in HIV-1 Infected Patients Completed NCT01111162 Phase 4
6 A Clinical Trial of Split-virion Influenza A/H1N1 Vaccines Completed NCT01004653 Phase 4
7 Post Authorization Safety Study of the Pandemic A/H1N1 Influenza Vaccines in Children and Adults Completed NCT01032980 Phase 4
8 Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults Completed NCT01008137 Phase 4
9 Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults With HIV Completed NCT01002040 Phase 4
10 Vaccine Responses to Influenza A H1N1/09 Immunization in High-risk Patients Completed NCT01022905 Phase 4
11 Safety of H1N1 Influenza Vaccination in Pregnant Women Completed NCT01842997 Phase 4
12 Rapid Evaluation of Pandemic H1N1 Influenza Vaccines in Young Children Completed NCT01000831 Phase 4
13 Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Aboriginal Children and Adults Completed NCT01001026 Phase 4
14 Rapid Evaluation of Pandemic H1N1 Influenza Vaccine in Adults Receiving Seasonal Influenza Vaccine Completed NCT01000584 Phase 4
15 Clinical Study to Evaluate Antibody and Cell Mediated Immunity of A/H1N1 Influenza Vaccine in Healthy Subjects Completed NCT01079273 Phase 4
16 Infectivity, Replication & Immunogenicity of Live nH1N1 Vaccine Completed NCT01023776 Phase 4
17 Vaccination Against Influenza in Autoimmune Diseases Completed NCT01065285 Phase 4
18 Phase IV Clinical Trial of an Influenza Split Vaccine Anflu Completed NCT00556062 Phase 4
19 A Study to Evaluate the Safety of H1N1 Monovalent Vaccine (MEDI3414) in Healthy Adults Completed NCT00945893 Phase 4
20 A Study to Evaluate the Safety of HIN1 Monovalent Vaccine (MEDI3414) in Children 2 to 17 Years of Age Completed NCT00946101 Phase 4
21 Study of GSK Biologicals' Influenza Vaccine Arepanrix™ in Japanese Adults 65 Years of Age or Older Completed NCT01114620 Phase 4
22 A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season Completed NCT01457027 Phase 4
23 Direct and Indirect Protection by Influenza Vaccine Given to Children in India Completed NCT00934245 Phase 4
24 Effect of Age and Prior Immunity on Response to H1N1 Vaccines in Children Withdrawn NCT01097941 Phase 4
25 Assessment of Needle-free Disposable-syringe Jet Injector (DSJI) ID Dose-sparing of Pandemic A H1N1 Influenza Vaccine Unknown status NCT01582633 Phase 2, Phase 3
26 Novel Influenza A/H1N1 Split- Virion Vaccine in Healthy Children Aged 6 to 35 Month Unknown status NCT01040078 Phase 3
27 Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Pediatric Subjects Completed NCT01000207 Phase 2, Phase 3
28 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children (3 to < 9 Years) Completed NCT00972816 Phase 2, Phase 3
29 Study of Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine in Healthy Adults in India Completed NCT01053143 Phase 3
30 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Children, Adolescents and Adults (3 to 64 Years) Completed NCT00973700 Phase 3
31 Safety and Immunogenicity of A/H1N1-SOIV (Swine Flu) Vaccine With and Without Adjuvant in Non-Elderly and Elderly Adults Completed NCT00973349 Phase 2, Phase 3
32 Single-blind, Dose-ranging Study of Novel Swine Influenza Virus Vaccine in Japanese Adult Subjects Completed NCT00996138 Phase 2, Phase 3
33 Clinical Trial to Compare the Immunogenicity, Safety, and Tolerability of an Adjuvanted A(H1N1) Influenza Vaccine Versus Non-Adjuvanted A(H1N1) Influenza Vaccines in Patients With Invasive Solid Tumors Completed NCT01031719 Phase 3
34 Immunogenicity, Safety, and Tolerability of MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With HIV-1 Infection Completed NCT01032408 Phase 3
35 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age Completed NCT00970177 Phase 3
36 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects 18 or More Years of Age Completed NCT00971906 Phase 3
37 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine in Healthy Subjects From 6 Months to 17 Years of Age Completed NCT00971100 Phase 3
38 Immunogenicity, Safety and Tolerability of Two Doses of Adjuvanted and Non-adjuvanted Swine Origin A/H1N1 Monovalent Influenza Vaccine (Egg-Derived) in Healthy Subjects From 6 Months to 17 Years of Age Completed NCT00971542 Phase 3
39 Immunogenicity and Safety Study of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults Completed NCT00989287 Phase 3
40 Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza (H1N1 Influenza Virus) Vaccine in Adults, Using Two Different Manufacturing Processes Completed NCT00992511 Phase 3
41 Does Seasonal Influenza Vaccination Affect the Incidence of pH1N1 Influenza? Completed NCT01001325 Phase 3
42 Immunogenicity, Safety, and Tolerability of an MF59-Adjuvanted Versus Non-Adjuvanted Influenza Vaccines in Patients With Chronic Pulmonary Disease, Chronic Heart Disease, or Diabetes Mellitus Completed NCT01032395 Phase 3
43 Pivotal, Multicenter, Observer-Blind, Randomized Study of Influenza A (H1N1)2009 Monovalent Subunit Vaccine With and Without Adjuvant in Children Ages 6 to <36 Months Completed NCT00996307 Phase 2, Phase 3
44 Safety and Efficacy of H1N1 Vaccines in Children Aged 6 Months to Less Than 10 Years of Age Completed NCT01051661 Phase 3
45 A Study to Evaluate the Safety and Immunogenicity of an Inactivated Split-virion Influenza A(H1N1) Vaccine Completed NCT01201902 Phase 3
46 Safety, Immunogenicity, and Relative Efficacy of H1N1 Vaccines in Adults Aged 18 Years and Older Completed NCT00979602 Phase 3
47 Study to Evaluate the Efficacy, Safety and Immunogenicity of Influenza Vaccine in Healthy Subjects (Aged 6 to <72 Months) Versus Control Vaccines Completed NCT00644059 Phase 3
48 A Clinical Trial Comparing Oseltamivir With Placebo And Zanamivir With Control As First Line Treatment For Human Swine Influenza Infection Terminated NCT00979667 Phase 3
49 Low Doses Corticosteroids as Adjuvant Therapy for the Treatment of Severe H1N1 Flu Terminated NCT01014364 Phase 3
50 Safety of and Immunogenicity to an H1N1 Influenza Vaccine in HIV-infected Adults Unknown status NCT01155037 Phase 2

Search NIH Clinical Center for Swine Influenza

Genetic Tests for Swine Influenza

Anatomical Context for Swine Influenza

MalaCards organs/tissues related to Swine Influenza:

39
Lung, Testes, T Cells, Neutrophil, Brain

The Foundational Model of Anatomy Ontology organs/tissues related to Swine Influenza:

18
Respiratory Tract Of Pigs

Publications for Swine Influenza

Articles related to Swine Influenza:

(show top 50) (show all 577)
id Title Authors Year
1
Biodegradable nanoparticle delivery of inactivated swine influenza virus vaccine provides heterologous cell-mediated immune response in pigs. ( 28057521 )
2017
2
Hidden authority study data have come to light: besides narcolepsy, the swine influenza vaccine Pandemrix caused type 1 diabetes. ( 27995691 )
2017
3
Maternally Derived Immunity Extends Swine Influenza A Virus Persistence within Farrow-to-Finish Pig Farms: Insights from a Stochastic Event-Driven Metapopulation Model. ( 27662592 )
2016
4
Pathogenic characteristics of a novel triple-reasserted H1N2 swine influenza virus. ( 27230301 )
2016
5
Erratum to: Maternally-derived antibodies do not prevent transmission ofA swine influenza A virus between pigs. ( 27653633 )
2016
6
A cross-sectional study of swine influenza in intensive and extensive farms in the northeastern region of the state of SALo Paulo, Brazil. ( 27637594 )
2016
7
Mycoplasma hyopneumoniae does not affect the interferon-related anti-viral response but predisposes the pig to a higher inflammation following swine influenza virus infection. ( 27498789 )
2016
8
Severe acute respiratory infection caused by swine influenza virus in a child necessitating extracorporeal membrane oxygenation (ECMO), the Netherlands, October 2016. ( 27934581 )
2016
9
In Vivo Validation of Predicted and Conserved T Cell Epitopes in a Swine Influenza Model. ( 27411061 )
2016
10
Effects of PB1-F2 on the pathogenicity of H1N1 swine influenza virus in mice and pigs. ( 28008819 )
2016
11
Prevalence, genetics, and transmissibility in ferrets of Eurasian avian-like H1N1 swine influenza viruses. ( 26711995 )
2016
12
Knowledge and Awareness Regarding Swine-Influenza A (H1N1) Virus Infection among Dental Professionals in India - A Systematic Review. ( 27790597 )
2016
13
Predicted Enhanced Human Propensity of Current Avian-Like H1N1 Swine Influenza Virus from China. ( 27828989 )
2016
14
Spillback transmission of European H1N1 avian-like swine influenza viruses to turkeys: A strain-dependent possibility? ( 27016764 )
2016
15
Truncation of C-terminal 20 amino acids in PA-X contributes to adaptation of swine influenza virus in pigs. ( 26912401 )
2016
16
Determination of current reference viruses for serological study of swine influenza viruses after the introduction of pandemic 2009 H1N1 (pdmH1N1) in Thailand. ( 27355862 )
2016
17
Virologic differences do not fully explain the diversification of swine influenza viruses in the United States. ( 27581984 )
2016
18
Protective efficacy of an inactivated Eurasian avian-like H1N1 swine influenza vaccine against homologous H1N1 and heterologous H1N1 and H1N2 viruses in mice. ( 27321744 )
2016
19
Adjuvant effects of invariant NKT cell ligand potentiates the innate and adaptive immunity to an inactivated H1N1 swine influenza virus vaccine in pigs. ( 27016770 )
2016
20
An Underestimated Co-infection: Swine Influenza and Pneumonia Due to Legionella pneumophila. ( 27650238 )
2016
21
Maternally-derived antibodies do not prevent transmission of swine influenza A virus between pigs. ( 27530456 )
2016
22
Distinct immune responses and virus shedding in pigs following aerosol, intra-nasal and contact infection with pandemic swine influenza A virus, A(H1N1)09. ( 27765064 )
2016
23
Rapid detection and subtyping of European swine influenza viruses in porcine clinical samples by haemagglutinin- and neuraminidase-specific tetra- and triplex real-time RT-PCRs. ( 27397600 )
2016
24
A Phylogeny-Based Global Nomenclature System and Automated Annotation Tool for H1 Hemagglutinin Genes from Swine Influenza A Viruses. ( 27981236 )
2016
25
The global antigenic diversity of swine influenza A viruses. ( 27113719 )
2016
26
H1N1 Swine Influenza Viruses Differ from Avian Precursors by a Higher pH Optimum of Membrane Fusion. ( 26608319 )
2016
27
Novel triple-reassortant H1N1 swine influenza viruses in pigs in Tianjin, Northern China. ( 26790939 )
2016
28
The Molecular Determinants of Antibody Recognition and Antigenic Drift in the H3 Hemagglutinin of Swine Influenza A Virus. ( 27384658 )
2016
29
Characterization of co-circulating swine influenza A viruses in North America and the identification of a novel H1 genetic clade with antigenic significance. ( 25701742 )
2015
30
Profile of the porcine acute-phase proteins response following experimental co-infection with H3N2 swine influenza virus and Pasteurella multocida. ( 26161700 )
2015
31
The effects of H3N2 swine influenza virus infection on TLRs and RLRs signaling pathways in porcine alveolar macrophages. ( 26021751 )
2015
32
Integrative analysis of differentially expressed microRNAs of pulmonary alveolar macrophages from piglets during H1N1 swine influenza A virus infection. ( 25639204 )
2015
33
Ceftiofur hydrochloride affects the humoral and cellular immune response in pigs after vaccination against swine influenza and pseudorabies. ( 26493336 )
2015
34
Genetic and biological characterization of two novel reassortant H5N6 swine influenza viruses in mice and chickens. ( 26296602 )
2015
35
Swine Influenza Virus and Association with the Porcine Respiratory Disease Complex in Pig Farms in Southern Brazil. ( 26302164 )
2015
36
Swine Influenza A(H3N2) Virus Infection in Immunocompromised Man, Italy, 2014. ( 26079745 )
2015
37
Acute appendicitis in a child with swine influenza (H1N1). ( 25814027 )
2015
38
Porcine interferon-induced protein with tetratricopeptide repeats 3, poIFIT3, inhibits swine influenza virus replication and potentiates IFN-I^ production. ( 25451299 )
2015
39
Poly I:C adjuvanted inactivated swine influenza vaccine induces heterologous protective immunity in pigs. ( 25437101 )
2015
40
Cross-protection against European swine influenza viruses in the context of infection immunity against the 2009 pandemic H1N1 virus: studies in the pig model of influenza. ( 26404790 )
2015
41
Detection and Isolation of Swine Influenza A Virus in Spiked Oral Fluid and Samples from Individually Housed, Experimentally Infected Pigs: Potential Role of Porcine Oral Fluid in Active Influenza A Virus Surveillance in Swine. ( 26431039 )
2015
42
Two different genotypes of H1N2 swine influenza virus isolated in northern China and their pathogenicity in animals. ( 25542286 )
2015
43
Molecular epidemiology study of swine influenza virus revealing a reassorted virus H1N1 in swine farms in Cuba. ( 25745869 )
2015
44
Altered splenic miRNA expression profile in H1N1 swine influenza. ( 25655261 )
2015
45
Molecular Characterisation of the Haemagglutinin Glycan-Binding Specificity of Egg-Adapted Vaccine Strains of the Pandemic 2009 H1N1 Swine Influenza A Virus. ( 26056814 )
2015
46
Carnosine markedly ameliorates H9N2 swine influenza virus-induced acute lung injury. ( 26233716 )
2015
47
Live poultry market workers are susceptible to both avian and swine influenza viruses, Guangdong Province, China. ( 26476563 )
2015
48
Mitochondrial antiviral signaling adaptor mediated apoptosis in H3N2 swine influenza virus infection is inhibited by viral protein NS1 in vitro. ( 25800220 )
2015
49
Dynamic Virus-Bacterium Interactions in a Porcine Precision-Cut Lung Slice Coinfection Model: Swine Influenza Virus Paves the Way for Streptococcus suis Infection in a Two-Step Process. ( 25916988 )
2015
50
Characterization of a novel oil-in-water emulsion adjuvant for swine influenza virus and Mycoplasma hyopneumoniae vaccines. ( 25936722 )
2015

Variations for Swine Influenza

Expression for Swine Influenza

Search GEO for disease gene expression data for Swine Influenza.

Pathways for Swine Influenza

GO Terms for Swine Influenza

Biological processes related to Swine Influenza according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 regulation of insulin secretion GO:0050796 9.16 SLC8B1 TNF
2 positive regulation of NIK/NF-kappaB signaling GO:1901224 8.96 AGO1 TNF
3 animal organ morphogenesis GO:0009887 8.8 FGD1 TNF TREH

Molecular functions related to Swine Influenza according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hydrolase activity, acting on glycosyl bonds GO:0016798 8.62 NEU1 TREH

Sources for Swine Influenza

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....